文献速递脑血管病头痛与眩晕

抗偏头痛CGRP受体拮抗剂加重小鼠脑缺血结局

Anti-migraine Calcitonin Gene-Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice.
PubMed 文献 · Ann Neurol · 2020-08-07

该研究在小鼠大脑中动脉闭塞模型中,发现CGRP受体拮抗剂gepants(olcegepant和rimegepant)增加梗死风险、梗死体积和神经功能缺损,并损害侧支循环和再灌注。提示这类偏头痛预防药物可能加重偶发脑缺血事件,需进一步明确脑血管安全性。

要点

  • olcegepant单次1mg/kg增加短暂缺血后的梗死风险(14/19 vs 6/18,RR=2.21)
  • olcegepant使60分钟闭塞后梗死体积翻倍并恶化神经功能(中位评分9 vs 5)
  • rimegepant 100mg/kg在60分钟闭塞后导致75%死亡率

核心结论

  • Gepants通过损害侧支循环加重小鼠缺血性卒中,提示CGRP通路阻断剂可能加重偶发脑缺血事件。

研究设计与样本

  • 小鼠大脑中动脉闭塞12-60分钟,比较olcegepant(单次或每日10次0.1-1mg/kg)或rimegepant(单次10-100mg/kg)与溶媒对梗死风险、体积、侧支血流和神经功能缺损的影响。

主要发现

  • olcegepant 1mg/kg单次使12-20分钟闭塞后梗死风险从6/18升至14/19(RR=2.21,p<0.022),60分钟闭塞后梗死体积翻倍(p<0.001)且神经功能缺损中位评分9 vs 5(p=0.008)。
  • olcegepant 0.1-1mg/kg每日10次结果相似。
  • rimegepant 10mg/kg使20分钟缺血后梗死体积增加60%(p=0.03);100mg/kg在60分钟闭塞后导致75%死亡率。
  • 家族性偏瘫性偏头痛1型小鼠中,olcegepant 1mg/kg使30分钟闭塞后梗死体积增加1.6倍(p=0.017)。
  • 两种gepants均持续减少侧支血流并降低再灌注成功率;olcegepant在小鼠主动脉CGRP诱导舒张中效力为rimegepant的10倍。

临床怎么用

  • 对偏头痛患者使用gepants时,应评估其脑缺血事件风险,尤其是已有缺血事件风险增高或正在接受CGRP通路预防治疗者。
  • 需进一步明确gepants的脑血管安全性,特别是在偶发脑缺血事件可能发生的患者中。

局限性

  • 研究为小鼠模型,结果不能直接外推至人类。
  • 未报告人类脑血管安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Calcitonin gene-related peptide (CGRP) pathway inhibitors are emerging treatments for migraine. CGRP-mediated vasodilation is, however, a critical rescue mechanism in ischemia. We, therefore, investigated whether gepants, small molecule CGRP receptor antagonists, worsen cerebral ischemia. METHODS: Middle cerebral artery was occluded for 12 to 60 minutes in mice. We compared infarct risk and volumes, collateral flow, and neurological deficits after pretreatment with olcegepant (single or 10 daily doses of 0.1-1mg/kg) or rimegepant (single doses of 10-100mg/kg) versus vehicle. We also determined their potency on CGRP-induced relaxations in mouse and human vessels, in vitro. RESULTS: Olcegepant (1mg/kg, single dose) increased infarct risk after 12- to 20-minute occlusions mimicking transient ischemic attacks (14/19 vs 6/18 with vehicle, relative risk = 2.21, p < 0.022), and doubled infarct volumes (p < 0.001) and worsened neurological deficits (median score = 9 vs 5 with vehicle, p = 0.008) after 60-minute occlusion. Ten daily doses of 0.1 to 1mg/kg olcegepant yielded similar results. Rimegepant 10mg/kg increased infarct volumes by 60% after 20-minute ischemia (p = 0.03); 100mg/kg caused 75% mortality after 60-minute occlusion. In familial hemiplegic migraine type 1 mice, olcegepant 1mg/kg increased infarct size after 30-minute occlusion (1.6-fold, p = 0.017). Both gepants consistently diminished collateral flow and reduced reperfusion success. Olcegepant was 10-fold more potent than rimegepant on CGRP-induced relaxations in mouse aorta. INTERPRETATION: Gepants worsened ischemic stroke in mice via collateral dysfunction. CGRP pathway blockers might thus aggravate coincidental cerebral ischemic events. The cerebrovascular safety of these agents must therefore be better delineated, especially in patients at increased risk of ischemic events or on prophylactic CGRP inhibition. ANN NEUROL 2020;88:771-784.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Mulder IA, Li M, de Vries T, et al. Anti-migraine Calcitonin Gene-Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice. Ann Neurol. 2020. PMID: 32583883. doi:10.1002/ana.25831

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。